Cited by 164PARP inhibition in cancer therapyBRCA gene mutations in cancerOvarian cancer diagnosis and treatment

The DOI matches its Crossref record; 99 of the 100 references it cites were found in a registry or an index.

PARP Inhibitors in Ovarian Cancer

Open access

Mittica, Gloria, Ghisoni, Eleonora, Giannone, Gaia, Genta, Sofia, Aglietta, Massimo, Sapino, Anna, Valabrega, Giorgio·2018·Recent Patents on Anti-Cancer Drug Discovery

DOI 10.2174/1574892813666180305165256

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: Treatment of Epithelial Ovarian Cancer (EOC), historically based on surgery and platinum doublet chemotherapy, is associated with high risk of relapse and poor prognosis for recurrent disease. In this landscape, the innovative treatment with PARP inhibitors (PARPis) demonstrated an outstanding activity in EOC, and is currently changing clinical practice in BRCA mutant patients. OBJECTIVES: The study aimed to highlight the mechanism of action, pharmacokinetics, clinical activity, indications and current strategies of development of Olaparib, Niraparib, Rucaparib, Talazoparib and Veliparib, the 5 most relevant PARPis. METHODS: We performed a review on Pubmed using 'ovarian cancer' and the name of each PARPi (PARP inhibitor) discussed in the review as Medical Subject Headings (MeSH) keywords. The same search was performed on "clinicaltrial.gov" to identify ongoing clinical trials and on "google. com/patents" and "uspto.gov" for recent patents exploring PARPIs in ovarian cancer. RESULTS: Olaparib, Niraparib and Rucaparib are already approved for the treatment of recurrent EOC and their indications are partially overlapping. Talazoparib and Veliparib are promising PARPis, but currently under investigation in early phase trials. Several studies are evaluating PARPis in monotherapy or in associations, in a wide range of settings (i.e. first line, neoadjuvant, platinum-sensitive and resistant disease). CONCLUSION: PARPis are valuable options in patients with recurrent ovarian cancer with promising activity in different stages of this disease. Further studies are required to better define optimal clinical settings, predictors of response beyond BRCA mutations and strategies to overcome secondary resistance of PARPis therapy in EOC.

Integrity signals

Registry

Crossref · 10.2174/1574892813666180305165256

Cites

99 of 99 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Signatures of mutational processes in human cancer
Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660
Integrated genomic analyses of ovarian carcinoma
Perou, C. M. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/hvp3-wg08 · Cited by 7,927
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683
Instability and decay of the primary structure of DNA
Lindahl, T. (1993) · Nature · doi:10.1038/362709a0 · Cited by 5,679
Genome maintenance mechanisms for preventing cancer
Hoeijmakers, J. H. J. (2001) · Nature · doi:10.1038/35077232 · Cited by 3,939
Average Risks of Breast and Ovarian Cancer Associated with BRCA1 or BRCA2 Mutations Detected in Case Series Unselected for Family History: A Combined Analysis of 22 Studies
Antoniou, A., Pharoah, P. D. P., Narod, S., Risch, H. A., Eyfjord, J. E., Hopper, J. L., Loman, N., Olsson, H., Johannsson, O., Borg, Å., et al. (2003) · The American Journal of Human Genetics · doi:10.1086/375033 · Cited by 3,680
Identification of the breast cancer susceptibility gene BRCA2
Wooster, R., Bignell, G. R., Lancaster, J., Swift, S., Seal, S., Mangion, J., Collins, N., Gregory, S. G., Gumbs, C. E., Micklem, G., et al. (1995) · Nature · doi:10.1038/378789a0 · Cited by 3,645
The mechanism of double-strand DNA break repair by the nonhomologous DNA end-joining pathway
Lieber, M. R. (2010) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.052308.093131 · Cited by 2,882
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
Audeh, M. W., Carmichael, J., Penson, R. T., Friedlander, M., Powell, B., Bell-McGuinn, K. M., Scott, C., Weitzel, J. N., Oaknin, A., Loman, N., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60893-8 · Cited by 2,279
Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors
Murai, J., Huang, S.-Y. N., Das, B. B., Renaud, A., Zhang, Y., Doroshow, J. H., Ji, J. J., Takeda, S., & Pommier, Y. G. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-2753 · Cited by 2,276

Show all 100 references

Sorted by citations

Items 101–164 of 164

Mechanism of PARP1 Elongation Reaction Revealed by Molecular Modeling
Pushkarev, S. V., Kirilin, E. M., Švedas, V. K., & Nilov, D. K. (2024) · Biochemistry (Moscow) · doi:10.1134/s0006297924070046 · Cited by 3
Beta-glucans is a Potential Inhibitor of Ovarian Cancer: Based on Molecular and Biological Aspects
Hallajzadeh, J., Sadoughi, F., Asemi, Z., Mansournia, M. A., & Yousefi, B. (2021) · Current Pharmaceutical Biotechnology · doi:10.2174/1389201022666210810090728 · Cited by 5
Potential Targeted Therapies in Ovarian Cancer
Sisman, Y., Vestergaard, L. K., Oliveira, D. V. N. P., Poulsen, T. S., Schnack, T. H., Høgdall, C. K., & Høgdall, E. V. S. (2022) · Pharmaceuticals · doi:10.3390/ph15111324 · Cited by 4
Recent trends in molecular testing and maintenance targeted therapies in ovarian cancer
Darwish, A., Elyashiv, O., Graham, R., & Miller, R. E. (2023) · The Obstetrician & Gynaecologist · doi:10.1111/tog.12880 · Cited by 3
Gentian Violet Inhibits Cell Proliferation through Induction of Apoptosis in Ovarian Cancer Cells
Choi, M. S., Kim, J. H., Lee, C. Y., Lee, Y. M., Lee, S., Chang, H. K., Kim, H. J., & Heo, K. (2023) · Biomedicines · doi:10.3390/biomedicines11061657 · Cited by 3
The first real-world study on the role of carbon ion radiotherapy for oligo-metastatic, persistent, or recurrent (MPR) ovarian/fallopian tube cancer
Barcellini, A., Murata, K., Fontana, G., Vai, A., Cassani, C., Landoni, F., Locati, L. D., Raspagliesi, F., Secondino, S., Pecorilla, M., et al. (2024) · Clinical and Translational Radiation Oncology · doi:10.1016/j.ctro.2024.100781 · Cited by 3
Long-Term Follow-Up of a Female Patient Treated with Olaparib—Hope for a Long Life without Relapse?
Kozłowski, M., Nowak, K., & Cymbaluk‐Płoska, A. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph18073430 · Cited by 3
Design, synthesis and biological evaluation of novel isoalantolactone-benzylamine derivatives leading to the discovery of a PARP1 inhibitor with selective cytotoxicity against MCF-7 breast cancer cells
Cui, B., Song, Y., Wang, X., Wang, Y., Chen, X., Yu, S., Man, D., Yuan, H., Piao, G., & Tian, Y. (2026) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2026.109521 · Cited by 2
Research progress on the association between environmental pollutants and the resistance mechanism of PARP inhibitors in ovarian cancer
Zhou, L., Xiang, J., & He, Y. (2021) · Environmental Science and Pollution Research · doi:10.1007/s11356-021-15852-9 · Cited by 2
Acute cardiac dysfunction in patients with ovarian cancer treated with Niraparib due to TFAM mutation: A case series and functional analysis
Liu, F., Liu, W., Li, D., Tu, C., Peng, X., & Wen, Y. (2025) · Cancer Genetics · doi:10.1016/j.cancergen.2025.05.006 · Cited by 2
Hydnocarpin, a Natural Flavonolignan, Induces the ROS-Mediated Apoptosis of Ovarian Cancer Cells and Reprograms Tumor-Associated Immune Cells
Kim, J., Kim, Y., Woo, S.-Y., Kim, J.-O., Kim, H., Son, S.-R., Jang, D. S., & Choi, J. (2025) · Antioxidants · doi:10.3390/antiox14070846 · Cited by 2
Benchmarking genetic interaction scoring methods for identifying synthetic lethality from combinatorial CRISPR screens
Ajmal, H. B., Nandi, S., Kebabci, N., & Ryan, C. J. (2025) · NAR Genomics and Bioinformatics · doi:10.1093/nargab/lqaf129 · Cited by 2
Surgery in platinum-resistant recurrent epithelial ovarian carcinoma
Zhao, L., Gao, W., Zhang, P., Zhang, Y., Fang, C., & Shou, H. (2022) · World Journal of Clinical Cases · doi:10.12998/wjcc.v10.i12.3739 · Cited by 2
Recent Developments in Combinatorial Immunotherapy towards Ovarian Cancer
Jain, C. K., Kulshreshtha, A., Saxena, H., Agarwal, A., & Passi, K. (2023) · Current Women s Health Reviews · doi:10.2174/1573404820666230505110617 · Cited by 2
Natural guanine derivatives exert PARP-inhibitory and cytoprotective effects in a model of cardiomyocyte damage under oxidative stress
Shram, S. I., Shcherbakova, T. A., Abramova, T. V., Baradieva, E. C., Efremova, A. S., Smirnovskaya, M. S., Silnikov, V. N., Švedas, V. K., & Nilov, D. K. (2023) · Biochemistry (Moscow) · doi:10.31857/s0320972523060064 · Cited by 2
Molecular Oncology of Gynecologic Tumors
Alvarado‐Cabrero, I. (2020) · Archives of Medical Research · doi:10.1016/j.arcmed.2020.09.001 · Cited by 2
The Power of Biomarkers in Transforming Patients Care in Gynecologic Oncology
Bairi, K. E., & Amrani, M. (2020) · Current Drug Targets · doi:10.2174/138945012110200624104942 · Cited by 2
Integrating Bioinformatics in Drug DiscoveryPreprint
Mustafa, M. I., Mohammed, A., Alzebair, A., & Makhawi, A. M. (2023) · Preprints.org · doi:10.20944/preprints202310.1465.v1 · Cited by 2
7-Methylguanine Inhibits Colon Cancer Growth in vivo
Игоревич, К. К., Fetisov, T. I., Antoshina, E. E., Gorkova, T. G., Trukhanova, L. S., Shram, S. I., Nagaev, I. Y., Zolotarev, Y. A., Qoura, L. A., Pokrovsky, V. S., et al. (2024) · Acta Naturae · doi:10.32607/actanaturae.27422 · Cited by 1
Endometriosis as a risk factor for ovarian cancer: an update on screening, risk reduction, treatment and prognosis
Campbell, R., Milford, K., Peyton‐Jones, B., & Hannemann, M. M. (2024) · The Obstetrician & Gynaecologist · doi:10.1111/tog.12948 · Cited by 1
The OvarianTag™ Biomarker Panel Emerges as a Prognostic Tool to Guide Clinical Decisions in Cisplatin-Based Treatment of Epithelial Ovarian Cancer
Braga, L. D. C., do Amaral, L. R., Delfino, P. H. V., Andrade, N. R., Salles, P. G. D. O., Filho, A. L. D. S., Bertarini, P. L. L., Ramos, A. P. Á. D. S., Gomes, M. D. S., & Silva, L. M. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26178393 · Cited by 1
Development and validation of a risk signature based on disulidptosis-related ferroptosis genes in ovarian cancer
Sun, Y., Liu, L., Guo, F., Jin, Z., Miao, Y., & Ma, Y. (2025) · Journal of Cancer Research and Therapeutics · doi:10.4103/jcrt.jcrt_28_25 · Cited by 1
PARPs in tumor immunology: Signal transduction and combination therapy for the future
Jiang, L., Peng, X., Yuan, W., Qu, J., Tan, J. W., Jiao, Q., Li, Y., Peng, Y., Cao, X., & Guo, Y. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.178298 · Cited by 1
Evaluation of the 1021-HRD assay compared to established HRD testing platforms in ovarian cancer
Papadopoulou, E., Fountzilas, E., Metaxa-Mariatou, V., Tsantikidi, A., Tsaousis, G., Meintani, A., Florou-Chatzigiannidou, C., Maxouri, S., Papazisis, K. T., Floros, T., et al. (2025) · Translational Oncology · doi:10.1016/j.tranon.2025.102621 · Cited by 1
Poly(ADP-ribose) polymerase (PARP) inhibitors in cardiovascular, and cerebrovascular diseases: mechanisms, current trends and challenge for clinical translation
Fan, J., & Song, Y. (2026) · PeerJ · doi:10.7717/peerj.20842 · Cited by 1
Pharmacological effects of Niraparib and its combination with angiogenic inhibitor in ovarian cancer
Liu, H., Chen, X., Tang, C., & Luo, X. (2023) · Journal of Cancer · doi:10.7150/jca.89082 · Cited by 1
Ocoxin Oral Solution Triggers DNA Damage and Cell Death in Ovarian Cancer
Postigo, S. A., Sanz, E., Pandiella, A., & Dı́az-Rodrı́guez, E. (2024) · Nutrients · doi:10.3390/nu16152416 · Cited by 1
Precision Medicine in Cancer
Ravichandiran, N., Barman, M. K., Lavuri, S. T., Srivastava, M., Sakthivel, S., Singh, M. M., Chand, K., Sonkar, S. C., & Bhukya, P. (2020) · Advances in medical diagnosis, treatment, and care (AMDTC) book series · doi:10.4018/978-1-7998-6530-8.ch015 · Cited by 1
Switching PARP inhibitors as an effective approach for niraparib‐induced erythema multiforme
Pesqué, D., Tormo‐Mainar, S., Bach, R., Recuero-Borau, J., & Pujol, R. M. (2022) · International Journal of Dermatology · doi:10.1111/ijd.16055 · Cited by 1
Non-BRCA1/BRCA2 High-Risk Familial Breast Cancers are Not Associated with a High Prevalence of BRCAnessPreprint
Andersen, L. V. B., Larsen, M. J., Davies, H. R., Degasperi, A., Nielsen, H. R., Kroeldrup, L., Gerdes, A., Lænkholm, A., Kruse, T. A., Nik‐Zainal, S., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-827829/v1 · Cited by 1
A quest through diagnostics and predictive tools and the exploration of new treatment strategies in clinical trials to improve cancer therapy
Heinhuis, K. M. (2020) · Utrecht University Repository (Utrecht University) · doi:10.33540/371
Zielgerichtete Therapie beim Ovarialkarzinom
Volkmer, A. K., Fehm, T. N., Meier, W., & Ruckhäberle, E. (2021) · Der Gynäkologe · doi:10.1007/s00129-020-04729-6
A Recent Update on the Clinical Trials and Effectiveness of Drugs Used in COVID-19, MERS and SARS Coronaviruses
Balef, S. S. H., Karimi, Z., Azari, A., Sadraei, S. S., Hasanjani, P., Sadeghi, Y., Ahmadi, S., Qorbannejad, F., Farmoudeh, A., & Irannejad, H. (2021) · Anti-Infective Agents · doi:10.2174/2211352519666210217100423
Overcoming drug resistance in ovarian cancer: Chemo-sensitizing agents, targeted therapies
Muppala, S. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-824299-5.00015-0
Systemische Therapie und zielgerichtete Erhaltungstherapie in der Primärsituation beim high- und low-grade Ovarialkarzinom
Ruckhäberle, E., & Fehm, T. N. (2022) · Der Gynäkologe · doi:10.1007/s00129-022-04907-8
Maintenance niraparib therapy for patients with relapsed platinum sensitive ovarian cancer: experience at a south coast network
Tomlins, E. (2022) · Journal of Prescribing Practice · doi:10.12968/jprp.2022.4.3.122
Distribution and Immunomodulatory mechanisms of Programmed death(PD)-1 molecule , its ligand PD-L1and related cytokines in Cervical CancerPreprint
Lin, Y., Wang, X., & Lin, W. (2020) · doi:10.22541/au.160029715.52951546
Association between Preoperative 18-FDG PET-CT SUVmax and Next-Generation Sequencing Results in Postoperative Ovarian Malignant Tissue in Patients with Advanced Ovarian Cancer
Ryu, J. M., Jeong, Y. Y., Lee, S.-J., Choi, B. W., & Choi, Y. S. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12062287
Poly(ADP-ribose) Polymerase Inhibitor Olaparib in the Treatment of Ovarian Cancer: A Comprehensive Review of Current Literature
Poboży, K., -, & - (2023) · Oncoreview · doi:10.24292/01.or.132020723
Inhibition of DNA ligase IV affects the DNA damage repair pathway and decreases the sensitivity of olaparib to platinum-sensitive BRCA wild-type ovarian cancerPreprint
Gu, Y., Pan, Y., Wang, Y., & Jiang, K. (2024) · Research Square · doi:10.21203/rs.3.rs-4842625/v1
The Poly ( ADP ‐Ribose) Polymerase‐1 Enzyme Is Overexpressed in Various Solid Canine Tumours: An Immunohistochemical Study
Vos, S. D., Janssen, S., Favril, S., Cock, H. D., Vynck, M., Steenbrugge, J., Spiegelaere, W. D., & de Rooster, H. (2025) · Veterinary and Comparative Oncology · doi:10.1111/vco.13053
The ENST00000539930 transcript predicts sensitivity to PARP inhibitors and clinical prognosis in cancers
Xu, C., Li, C., Wang, W., Li, Y., Wang, T., Sun, F., Yang, X., Li, C., & Ma, F. (2025) · ONCOLOGIE · doi:10.1515/oncologie-2025-0144
Upregulation of NR4A3 increases sensitivity to niraparib in ovarian cancer cells resistant to this drug
Wang, J., Yu, W., & Chen, B. (2025) · Journal of Molecular Histology · doi:10.1007/s10735-025-10490-8
Additional file 2 of Comprehensive analysis of prognostic gene signatures based on immune infiltration of ovarian cancer
Yan, S., Fang, J., Chen, Y., Xie, Y., Zhang, S., Zhu, X., & Fang, F. (2020) · Figshare · doi:10.6084/m9.figshare.13346212
Additional file 6 of Comprehensive analysis of prognostic gene signatures based on immune infiltration of ovarian cancer
Yan, S., Fang, J., Chen, Y., Xie, Y., Zhang, S., Zhu, X., & Fang, F. (2020) · Figshare · doi:10.6084/m9.figshare.13346224
Additional file 3 of Non-BRCA1/BRCA2 high-risk familial breast cancers are not associated with a high prevalence of BRCAness
Andersen, L. V. B., Larsen, M. J., Davies, H., Degasperi, A., Nielsen, H. R., Jensen, L. A., Kroeldrup, L., Gerdes, A.-M., Lænkholm, A.-V., Kruse, T. A., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26597108
Additional file 7 of Non-BRCA1/BRCA2 high-risk familial breast cancers are not associated with a high prevalence of BRCAness
Andersen, L. V. B., Larsen, M. J., Davies, H., Degasperi, A., Nielsen, H. R., Jensen, L. A., Kroeldrup, L., Gerdes, A.-M., Lænkholm, A.-V., Kruse, T. A., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26597120
Additional file 4 of Comprehensive analysis of prognostic gene signatures based on immune infiltration of ovarian cancer
Yan, S., Fang, J., Chen, Y., Xie, Y., Zhang, S., Zhu, X., & Fang, F. (2020) · Figshare · doi:10.6084/m9.figshare.13346218
Additional file 5 of Non-BRCA1/BRCA2 high-risk familial breast cancers are not associated with a high prevalence of BRCAness
Andersen, L. V. B., Larsen, M. J., Davies, H., Degasperi, A., Nielsen, H. R., Jensen, L. A., Kroeldrup, L., Gerdes, A.-M., Lænkholm, A.-V., Kruse, T. A., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26597114
Additional file 2 of Non-BRCA1/BRCA2 high-risk familial breast cancers are not associated with a high prevalence of BRCAness
Andersen, L. V. B., Larsen, M. J., Davies, H., Degasperi, A., Nielsen, H. R., Jensen, L. A., Kroeldrup, L., Gerdes, A.-M., Lænkholm, A.-V., Kruse, T. A., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26597105
Additional file 9 of Non-BRCA1/BRCA2 high-risk familial breast cancers are not associated with a high prevalence of BRCAness
Andersen, L. V. B., Larsen, M. J., Davies, H., Degasperi, A., Nielsen, H. R., Jensen, L. A., Kroeldrup, L., Gerdes, A.-M., Lænkholm, A.-V., Kruse, T. A., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26597126
Additional file 4 of Non-BRCA1/BRCA2 high-risk familial breast cancers are not associated with a high prevalence of BRCAness
Andersen, L. V. B., Larsen, M. J., Davies, H., Degasperi, A., Nielsen, H. R., Jensen, L. A., Kroeldrup, L., Gerdes, A.-M., Lænkholm, A.-V., Kruse, T. A., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26597111
Additional file 1 of Non-BRCA1/BRCA2 high-risk familial breast cancers are not associated with a high prevalence of BRCAness
Andersen, L. V. B., Larsen, M. J., Davies, H., Degasperi, A., Nielsen, H. R., Jensen, L. A., Kroeldrup, L., Gerdes, A.-M., Lænkholm, A.-V., Kruse, T. A., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26597102
Additional file 1 of Comprehensive analysis of prognostic gene signatures based on immune infiltration of ovarian cancer
Yan, S., Fang, J., Chen, Y., Xie, Y., Zhang, S., Zhu, X., & Fang, F. (2020) · Figshare · doi:10.6084/m9.figshare.13346209
Additional file 3 of Comprehensive analysis of prognostic gene signatures based on immune infiltration of ovarian cancer
Yan, S., Fang, J., Chen, Y., Xie, Y., Zhang, S., Zhu, X., & Fang, F. (2020) · Figshare · doi:10.6084/m9.figshare.13346215
Additional file 8 of Non-BRCA1/BRCA2 high-risk familial breast cancers are not associated with a high prevalence of BRCAness
Andersen, L. V. B., Larsen, M. J., Davies, H., Degasperi, A., Nielsen, H. R., Jensen, L. A., Kroeldrup, L., Gerdes, A.-M., Lænkholm, A.-V., Kruse, T. A., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26597123
Additional file 5 of Comprehensive analysis of prognostic gene signatures based on immune infiltration of ovarian cancer
Yan, S., Fang, J., Chen, Y., Xie, Y., Zhang, S., Zhu, X., & Fang, F. (2020) · Figshare · doi:10.6084/m9.figshare.13346221
Additional file 6 of Non-BRCA1/BRCA2 high-risk familial breast cancers are not associated with a high prevalence of BRCAness
Andersen, L. V. B., Larsen, M. J., Davies, H., Degasperi, A., Nielsen, H. R., Jensen, L. A., Kroeldrup, L., Gerdes, A.-M., Lænkholm, A.-V., Kruse, T. A., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26597117
Additional file 7 of Comprehensive analysis of prognostic gene signatures based on immune infiltration of ovarian cancer
Yan, S., Fang, J., Chen, Y., Xie, Y., Zhang, S., Zhu, X., & Fang, F. (2020) · Figshare · doi:10.6084/m9.figshare.13346227
Additional file 10 of Non-BRCA1/BRCA2 high-risk familial breast cancers are not associated with a high prevalence of BRCAness
Andersen, L. V. B., Larsen, M. J., Davies, H., Degasperi, A., Nielsen, H. R., Jensen, L. A., Kroeldrup, L., Gerdes, A.-M., Lænkholm, A.-V., Kruse, T. A., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26597129
Cancers épithéliaux de l'ovaire : évaluation des profils génomiques identifiés selon une approche phénotypique, histologique et bio-statistique
Eymerit-Morin, C. (2021) · doi:10.70675/cf7a9d8ez16a0z4bd4z870az032bea313bc2
Development of an homologous recombination deficiency scoring algorithm for unmatched ovarian tumor sample based on next-generation sequencing
Wang, Z., Yang, X., Cheng, T., Feng, J., Zheng, J., Wang, T., Zhang, M., Meng, H., Jiang, C., & Wei, B. (2026) · Journal of Gynecologic Oncology · doi:10.3802/jgo.2026.37.e97
Combining an α v β 6 -Targeted 177 Lu-Based Peptide Receptor Radionuclide Therapy with Olaparib to Boost Therapeutic Efficacy in Pancreatic Cancer
Ganguly, T., Harris, R. E., Hausner, S. H., & Sutcliffe-Goulden, J. (2026) · Journal of Nuclear Medicine · doi:10.2967/jnumed.125.271137
BindingDB Entry 50021343: High affinity and low PARP-trapping benzimidazole derivatives as a potential warhead for PARP1 degraders.
BindingDB (2025) · UC San Diego · doi:10.7270/q21n85rf

Authors: Mittica, G., Ghisoni, E., Giannone, G., Genta, S., Aglietta, M., Sapino, A., & Valabrega, G.
Affiliations: Candiolo Cancer Institute (IT)
Corresponding author: Valabrega, Giorgio
ORCID: Ghisoni, Eleonora
Giannone, Gaia
Genta, Sofia
Aglietta, Massimo
Sapino, Anna
Valabrega, Giorgio
Venue: Recent Patents on Anti-Cancer Drug Discovery
Publisher: Bentham Science Publishers Ltd.
Published: 2018-10-03
Volume: 13
Issue: 4
Pages: 392-410
ISSN: 1574-8928 (ISSN-L)
DOI: 10.2174/1574892813666180305165256
OpenAlex: W2794128499
Cited by: 158
References: 100
Citations by year: 2026: 5 · 2025: 16 · 2024: 21 · 2023: 29 · 2022: 20 · 2021: 27 · 2020: 28 · 2019: 11 · 2018: 1
FWCI: 6.28
Type: journal article
Language: en
Open access: green
hdl.handle.net
Licence: other-oa
Locations: Recent Patents on Anti-Cancer Drug Discovery (publishedVersion)
PubMed (publishedVersion)
Institutional Research Information System University of Turin (University of Turin) (submittedVersion, other-oa)
Topics: Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
Health Sciences › Medicine › Oncology › Ovarian cancer diagnosis and treatment
Keywords: PARP inhibitors, epithelial ovarian cancer, recurrent ovarian cancer, olaparib, niraparib, rucaparib, talazoparib, veliparib, BRCA mutations, platinum resistance, secondary resistance, mechanism of action, pharmacokinetics, neoadjuvant therapy, first-line therapy, combination therapy
MeSH terms: Poly(ADP-ribose) Polymerase Inhibitors, Animals, Antineoplastic Agents, Female, Humans, Ovarian Neoplasms, Phthalazines, Piperazines, Drug Resistance, Neoplasm

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

PARP Inhibitors in Ovarian Cancer

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks